Restoring Health Through Innovation
Our proprietary approach is based around the functional preservation of key natural enzymes responsible for lipid (fat) metabolism. Our developing first in class biologic looks to revolutionize the treatment of obesity related diseases, with a primary focus on hyperlipidemia.
Although iMBP is an early stage company, it has assembled a seasoned group of clinical, research and business leaders as a formidable team to make our drug and business a success.
Driven by innovation, iMetabolic Biopharma Corporation (iMBP) has been focused on developing safe & effective First IN Class therapeutics that will support physicians in their battle against obesity related diseases. Across the globe, these solutions are essential to mitigating both the health and financial risks associated with these diseases. This can only be achieved by emphasizing healthcare provider and patient success; therefore both iMBP management and researchers are focusing on the innovation of products that ensure efficacy, safety and affordability.
Through strategic planning and precise execution, iMetabolic Biopharma Corporation has established it’s self as a virtual precision medicine biopharma company. By gaining access to world leading research facilities and their experts, a cost effective and efficient approach to the iMetabolic Biopharma DDD process has been established.
Dr. Urban A. Kiernan - Founder, CEO and Board Chairman. With 20 years of industry business and research experience, Dr. Kiernan is the lead architect in the development of what has now become iMBP. Prior to focusing on iMBP, he was the Director of Biomarker Discovery at Intrinsic Bioprobes Incorporated and later established himself as a Global Business Development Manager for Thermo Fisher Scientific.
Dr. Stephen A. Munk - Interim - COO and Board Director. Dr. Munk has over 25 years of experience in the life science and pharmaceutical industry. He currently serves as the Deputy Director of the Biodesign Institute at Arizona State University, but spent the last two decades as the as the CEO of Ash Stevens Inc, a full service Active Pharmaceutical Ingredient (API) development and manufacturing organization. Under his leadership, Ash Stevens received twelve FDA approvals to manufacture innovator drug substances and received six NIH research contacts.
Mr. Jeffrey D. Zimmerman, Esq. - General Counsel & Board Secretary. Mr. Zimmerman has over three decades of business law expertise. His experience ranges from direct business advisement through complex merger and acquisitions. He also has extensive experience through his participation on the Boards of several not for profit organizations.
Mr. Bobby Mikkelsen - VP of Finance. With over a decade of business accounting & finance experience under his belt, Mr. Mikkelsen brings a new dimension to the team for the execution of iMBP Corporation's developing business strategy. Along with his finance skill and expertise, he provides the company with access to his full service accounting firm for improved operations and ensured compliance of sound accounting practice.
Mr. David F. Hendren - Managing Dir; Augmentum Advisers, LLC. David has 25+ years of experience in building, funding and launching healthcare, life sciences and bio-medically related companies. He has participated in companies that were able to execute IPO, M&A and licensing exit strategies.
Mr. André Harrell - CEO; AH2 & Beyond Consulting. With an industrial life science career that spans three decades, Mr. Harrell has worked with many notable Fortune 100 companies such as Johnson & Johnson Inc, Hewlett Packard, BASF, SC Johnson, Bristol Myers Squibb, Mylan Pharmaceutical, Revlon Professional, Twitter, and Novo Nordisk. Through his efforts he has amassed extensive experience in global commercial strategies and corporate development.
Dr. Martin Emanuele - Co-Founder & COO; Visgenx. With over 30 years of bio-pharmaceutical industry experience; including over two decades in senior executive roles in companies that include CytRx Corp., Avanir Pharmaceuticals and Mast Therapeutics, Dr. Emanuale has experience in developing both research and business teams that have resulted in multiple IND and NDA approvals.
Dr. Stephen Naylor - Dr. Naylor has over 30 years of experience in the health and life sciences. He is the former Chief Technology Officer of Beyond Genomics and has held various professional positions at many world renowned academic institutions.
Dr. Gerald I. Shulman - Research Professor. Howard Hughes Medical Instituite, Yale University School of Medicine
Dr. Michael R. Briggs - President. Woodland Pharmaceuticals, LLC
Dr. Martin Emanuele - Co-Founder. LifeRaft, Inc.
Dr. Randall W. Nelson - Research Professor (Retired). Molecular Biosignatures Analysis Unit, Biodesign, ASU
Dr. Christopher Larson - Vice President & Adjunct Assoc. Professor. Sanford Burnham Presbys Medical Discovery Institute
Dr. Kirkwood A. Pritchard Jr. - Tenured Professor. Medical College of Wisconsin
Dr. Kitt Falk Petersen - Endocrinologist. Yale University School of Medicine
Dr. Damon Dixon - Cardiologist & Lipidologist. Phoenix Children's Hospital
Dr. H. Randall Craig - Endocrinologist (Fertility Specialist). Fertility Treatment Center